AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Recruiting now Phase 3 NCT07339423
Run by Novo Nordisk A/S · for 18 and older · All sexes
What this study is about
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Who can join (things the study team will check)
✅ You may be able to join if…
- Male or female (sex at birth).
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- History of at least one self-reported unsuccessful dietary effort to lose body weight.
🚫 You may not be able to join if…
- HbA1c ≥ 6.5% (48 millimole per mole [mmol/mol]) as measured by the central laboratory at screening.
- History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
- Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.
Where this trial is running
- South Broward Research LLC, Miramar, Florida, United States
- Clinical Neuroscience Solution, Orlando, Florida, United States
- Hope Clin Res & Wellness, Conyers, Georgia, United States
- Endeavor Health, Skokie, Illinois, United States
- Midwest Inst For Clin Res, Indianapolis, Indiana, United States
- StudyMetrix Research LLC, City of Saint Peters, Missouri, United States
- New York Gastroenterology Associates, New York, New York, United States
- UNC Eastowne Medical Office, Chapel Hill, North Carolina, United States
- PharmQuest Life Sciences LLC, Greensboro, North Carolina, United States
- Accellacare and KDCILM, LLC, Wilmington, North Carolina, United States
- UPA Ctr Weight and Eating Dis, Philadelphia, Pennsylvania, United States
- Clinical Res Collaborative, Cumberland, Rhode Island, United States
+ 60 more sites.
Who to contact
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07339423.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.